Chronic hepatitis C virus infection and increases in viral load in a prospective cohort of young, HIV-uninfected injection drug users

Drug and Alcohol Dependence

Volumn 119, Issue 3, 2011, Pages 166-171

  Boodram, Basmattee ^a   Hershow, Ronald C ^a   Cotler, Scott J ^a   Ouellet, Lawrence J ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Chronic; Hepatitis C; Injection drug use; Longitudinal; Viral load

Indexed keywords

HEPATITIS C VACCINE; VIRUS RNA;

ADULT; AGE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DRUG ABUSE; ETHNICITY; FEMALE; GENDER; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION; INJECTION DRUG ABUSE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; SEROLOGY; TREATMENT RESPONSE; UNITED STATES; VIRUS LOAD;

ADOLESCENT; ADULT; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; PROSPECTIVE STUDIES; SUBSTANCE ABUSE, INTRAVENOUS; VIRAL LOAD; YOUNG ADULT;

HEPATITIS C VIRUS;

EID: 82555192456     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2011.06.005     Document Type: Article

References (48)

1. Alter M.J. Epidemiology of hepatitis C in the West. Semin. Liver Dis. 1995, 15:5-14.
2. Alter M.J. Epidemiology of hepatitis C virus infection. World J. Gastroenterol. 2007, 13:2436-2441.
3. Alter M.J., Kruszon-Moran D., Nainan O.V., McQuillan G.M., Gao F., Moyer L.A., Kaslow R.A., Margolis H.S. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med. 1999, 341:556-562.
4. Alter M.J., Margolis H.S., Krawczynski K., Judson F.N., Mares A., Alexander W.J., Hu P.Y., Miller J.K., Gerber M.A., Sampliner R.E., et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N. Engl. J. Med. 1992, 327:1899-1905.
5. Armstrong G.L., Wasley A., Simard E.P., McQuillan G.M., Kuhnert W.L., Alter M.J. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann. Intern. Med. 2006, 144:705-714.
6. Berger A., von Depka Prondzinski M., Doerr H.W., Rabenau H., Weber B. Hepatitis C plasma viral load is associated with HCV genotype but not with HIV coinfection. J. Med. Virol. 1996, 48:339-343.
7. Broz D., Ouellet L.J. Racial and ethnic changes in heroin injection in the United States: implications for the HIV/AIDS epidemic. Drug Alcohol Depend. 2008, 94:221-233.
8. Broz D., Ouellet L.J. Prevalence and correlates of former injection drug use among young noninjecting heroin users in Chicago. Subst. Use Misuse 2010, 45:2000-2025.
9. Cribier B., Rey D., Schmitt C., Lang J.M., Kirn A., Stoll-Keller F. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS 1995, 9:1131-1136.
10. Des Jarlais D.C., Paone D., Milliken J., Turner C.F., Miller H., Gribble J., Shi Q., Hagan H., Friedman S.R. Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: a quasi-randomised trial. Lancet 1999, 353:1657-1661.
11. DuBois D.B., Gretch D., dela Rosa C., Lee W., Fine J., Blagg C.R., Corey L. Quantitation of hepatitis C viral RNA in sera of hemodialysis patients: gender-related differences in viral load. Am. J. Kidney Dis. 1994, 24:795-801.
12. Eyster M.E., Fried M.W., Di Bisceglie A.M., Goedert J.J. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood 1994, 84:1020-1023.
13. Farci P., Shimoda A., Coiana A., Diaz G., Peddis G., Melpolder J.C., Strazzera A., Chien D.Y., Munoz S.J., Balestrieri A., Purcell R.H., Alter H.J. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000, 288:339-344.
14. Fishbein D.A., Lo Y., Netski D., Thomas D.L., Klein R.S. Predictors of hepatitis C virus RNA levels in a prospective cohort study of drug users. J. Acquir. Immune Defic. Syndr. 2006, 41:471-476.
15. Garfein R.S., Swartzendruber A., Ouellet L.J., Kapadia F., Hudson S.M., Thiede H., Strathdee S.A., Williams I.T., Bailey S.L., Hagan H., Golub E.T., Kerndt P., Hanson D.L., Latka M.H. Methods to recruit and retain a cohort of young-adult injection drug users for the Third Collaborative Injection Drug Users Study/Drug Users Intervention Trial (CIDUS III/DUIT). Drug Alcohol Depend. 2007, 91(Suppl. 1):S4-S17.
16. Global Burden of Hepatitis C Work Group The global burden of hepatitis C. J. Clin. Pharmacol. 2004, 204:20-29.
17. Gordon S.C., Dailey P.J., Silverman A.L., Khan B.A., Kodali V.P., Wilber J.C. Sequential serum hepatitis C viral RNA levels longitudinally assessed by branched DNA signal amplification. Hepatology 1998, 28:1702-1706.
18. Halfon P., Bourliere M., Halimi G., Khiri H., Bertezene P., Portal I., Botta-Fridlund D., Gauthier A.P., Jullien M., Feryn J.M., Gerolami V., Cartouzou G. Assessment of spontaneous fluctuations of viral load in untreated patients with chronic hepatitis C by two standardized quantitation methods: branched DNA and Amplicor Monitor. J. Clin. Microbiol. 1998, 36:2073-2075.
19. Heckathorn D. Respondent-driven sampling: a new approach to the study of hidden populations. Soc. Probl. 1997, 44:174-199.
20. Hisada M., Chatterjee N., Kalaylioglu Z., Battjes R.J., Goedert J.J. Hepatitis C virus load and survival among injection drug users in the United States. Hepatology 2005, 42:1446-1452.
21. Hollingsworth R.C., Sillekens P., van Deursen P., Neal K.R., Irving W.L. Serum HCV RNA levels assessed by quantitative NASBA: stability of viral load over time, and lack of correlation with liver disease. The Trent HCV Study Group. J. Hepatol. 1996, 25:301-306.
22. Hoofnagle J.H. Course and outcome of hepatitis C. Hepatology 2002, 36:S21-S29.
23. Idrees M., Riazuddin S. A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients. BMC Gastroenterol. 2009, 9:5.
24. Kuramoto I.K., Moriya T., Schoening V., Holland P.V. Fluctuation of serum HCV-RNA levels in untreated blood donors with chronic hepatitis C virus infection. J. Viral Hepat. 2002, 9:36-42.
25. Latka M., Ahern J., Garfein R.S., Ouellet L., Kerndt P., Morse P., Farshy C.E., Des Jarlais D.C., Vlahov D. Prevalence, incidence, and correlates of chlamydia and gonorrhea among young adult injection drug users. J. Subst. Abuse 2001, 13:73-88.
26. Martell M., Esteban J.I., Quer J., Genesca J., Weiner A., Esteban R., Guardia J., Gomez J. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J. Virol. 1992, 66:3225-3229.
27. McCormick S.E., Goodman Z.D., Maydonovitch C.L., Sjogren M.H. Evaluation of liver histology, ALT elevation, and HCV RNA titer in patients with chronic hepatitis C. Am. J. Gastroenterol. 1996, 91:1516-1522.
28. Minuk G.Y. The influence of host factors on the natural history of chronic hepatitis C viral infections. J. Viral Hepat. 1999, 6:271-276.
29. Neaigus A., Gyarmathy V.A., Miller M., Frajzyngier V.M., Friedman S.R., Des Jarlais D.C. Transitions to injecting drug use among noninjecting heroin users: social network influence and individual susceptibility. J. Acquir. Immune Defic. Syndr. 2006, 41:493-503.
30. Operskalski E.A., Mack W.J., Strickler H.D., French A.L., Augenbraun M., Tien P.C., Villacres M.C., Spencer L.Y., Degiacomo M., Kovacs A. Factors associated with hepatitis C viremia in a large cohort of HIV-infected and -uninfected women. J. Clin. Virol. 2008, 41:255-263.
31. Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997, 349:825-832.
32. Poynard T., Marcellin P., Lee S.S., Niederau C., Minuk G.S., Ideo G., Bain V., Heathcote J., Zeuzem S., Trepo C., Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998, 352:1426-1432.
33. Puoti C., Stati T., Magrini A. Serum HCV RNA titer does not predict the severity of liver damage in HCV carriers with normal aminotransferase levels. Liver 1999, 19:104-109.
34. Pyrsopoulos N., Jeffers L. Hepatitis C in African Americans. J. Clin. Gastroenterol. 2007, 41:185-193.
35. Quinn P.G., Jamal M.M., Carey J.D., Arora S., Harris T., Johnston D.E., Sonnenberg A. A case-control study of the factors associated with spontaneous resolution of hepatitis C viremia. Am. J. Gastroenterol. 1999, 94:668-673.
36. Shakil A.O., Conry-Cantilena C., Alter H.J., Hayashi P., Kleiner D.E., Tedeschi V., Krawczynski K., Conjeevaram H.S., Sallie R., Di Bisceglie A.M. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann. Intern. Med. 1995, 123:330-337.
37. Soriano V., Mocroft A., Rockstroh J., Ledergerber B., Knysz B., Chaplinskas S., Peters L., Karlsson A., Katlama C., Toro C., Kupfer B., Vogel M., Lundgren J. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J. Infect. Dis. 2008, 198:1337-1344.
38. Strasfeld L., Lo Y., Netski D., Thomas D.L., Klein R.S. The association of hepatitis C prevalence, activity, and genotype with HIV infection in a cohort of New York City drug users. J. Acquir. Immune Defic. Syndr. 2003, 33:356-364.
39. Sylvestre D.L., Clements B.J. The utility of indirect predictors of hepatitis C viremia. Drug Alcohol Depend. 2004, 74:15-19.
40. Thomas D.L., Astemborski J., Rai R.M., Anania F.A., Schaeffer M., Galai N., Nolt K., Nelson K.E., Strathdee S.A., Johnson L., Laeyendecker O., Boitnott J., Wilson L.E., Vlahov D. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000, 284:450-456.
41. Thomas D.L., Astemborski J., Vlahov D., Strathdee S.A., Ray S.C., Nelson K.E., Galai N., Nolt K.R., Laeyendecker O., Todd J.A. Determinants of the quantity of hepatitis C virus RNA. J. Infect. Dis. 2000, 181:844-851.
42. Thomas D.L., Rich J.D., Schuman P., Smith D.K., Astemborski J.A., Nolt K.R., Klein R.S. Multicenter evaluation of hepatitis C RNA levels among female injection drug users. J. Infect. Dis. 2001, 183:973-976.
43. Thomas D.L., Seeff L.B. Natural history of hepatitis C. Clin. Liver Dis. 2005, 9:383-398. vi.
44. Thomas D.L., Thio C.L., Martin M.P., Qi Y., Ge D., O'Huigin C., Kidd J., Kidd K., Khakoo S.I., Alexander G., Goedert J.J., Kirk G.D., Donfield S.M., Rosen H.R., Tobler L.H., Busch M.P., McHutchison J.G., Goldstein D.B., Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-801.
45. Torriani F.J., Rodriguez-Torres M., Rockstroh J.K., Lissen E., Gonzalez-Garcia J., Lazzarin A., Carosi G., Sasadeusz J., Katlama C., Montaner J., Sette H., Passe S., De Pamphilis J., Duff F., Schrenk U.M., Dieterich D.T. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N. Engl. J. Med. 2004, 351:438-450.
46. Turner C.F., Ku L., Rogers S.M., Lindberg L.D., Pleck J.H., Sonenstein F.L. Adolescent sexual behavior, drug use, and violence: increased reporting with computer survey technology. Science 1998, 280:867-873.
47. Yeo A.E., Ghany M., Conry-Cantilena C., Melpolder J.C., Kleiner D.E., Shih J.W., Hoofnagle J.H., Alter H.J. Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers. J. Viral Hepat. 2001, 8:256-263.
48. Yoshimura E., Hayashi J., Ueno K., Kishihara Y., Yamaji K., Etoh Y., Kashiwagi S. No significant changes in levels of hepatitis C virus (HCV) RNA by competitive polymerase chain reaction in blood samples from patients with chronic HCV infection. Dig. Dis. Sci. 1997, 42:772-777.